Literature DB >> 7880745

Intra-arterial chemotherapy in patients with breast cancer: a feasibility study.

W G Lewis1, V A Walker, H H Ali, J R Sainsbury.   

Abstract

The aim of this study was to assess the practicality of treating patients with various stages of breast cancer by means of regional (intra-arterial) chemotherapy. Three groups of patients received a median of four (range 2-4) cycles of combination chemotherapy: group I operable primary (n = 10); group II, locally advanced disease (n = 20); group III, recurrent locoregional disease (n = 22). The response rates (complete response, partial response and mixed response) in these groups of patients were 100% in groups I and II and 86% in group III. Morbidity included drug streaming and dysaesthesia in the hand. Patients in groups I and II had their tumours downstaged, allowing surgery to be performed. Local control was also achieved in group III when other treatment modalities had failed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7880745      PMCID: PMC2033640          DOI: 10.1038/bjc.1995.117

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  9 in total

1.  Chemotherapy of breast cancer by regional intra-arterial infusion.

Authors:  H A Freckman
Journal:  Cancer       Date:  1970-09       Impact factor: 6.860

2.  Intra-arterial cytotoxic therapy and x-ray therapy for cancer of the breast.

Authors:  P Helman; M B Bennett
Journal:  Br J Surg       Date:  1968-06       Impact factor: 6.939

3.  Transcatheter embolisation to control severe bleeding in fungating breast cancer.

Authors:  E M Rankin; R D Rubens; J F Reidy
Journal:  Eur J Surg Oncol       Date:  1988-02       Impact factor: 4.424

4.  Initial chemoimmunotherapy in inflammatory carcinoma of the breast.

Authors:  B Zylberberg; J Salat-Baroux; J H Ravina; D Dormont; J P Amiel; P Diebold; V Izrael
Journal:  Cancer       Date:  1982-04-15       Impact factor: 6.860

5.  Intraarterial induction chemotherapy in locally advanced stage III breast cancer.

Authors:  F O Stephens
Journal:  Cancer       Date:  1990-08-15       Impact factor: 6.860

6.  Primary medical therapy for operable breast cancer.

Authors:  J L Mansi; I E Smith; G Walsh; R P A'Hern; C L Harmer; H D Sinnett; P A Trott; C Fisher; J A McKinna
Journal:  Eur J Cancer Clin Oncol       Date:  1989-11

7.  Aggressive combined modality therapy for advanced local-regional breast carcinoma.

Authors:  C L Loprinzi; P P Carbone; D C Tormey; P R Rosenbaum; W Caldwell; J C Kline; R A Steeves; G Ramirez
Journal:  J Clin Oncol       Date:  1984-03       Impact factor: 44.544

8.  The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer.

Authors:  R B Jones; E J Shpall; J Shogan; M L Affronti; D Coniglio; L Hart; E Halperin; J D Iglehart; J Moore; J Gockerman
Journal:  Cancer       Date:  1990-08-01       Impact factor: 6.860

9.  Management of inflammatory carcinoma of the breast with combined modality therapy including intraarterial infusion chemotherapy as an induction therapy. Long-term follow-up results of 28 patients.

Authors:  S Noguchi; K Miyauchi; Y Nishizawa; H Koyama; T Terasawa
Journal:  Cancer       Date:  1988-04-15       Impact factor: 6.860

  9 in total
  1 in total

Review 1.  Breast cancer.

Authors:  R Sainsbury
Journal:  Postgrad Med J       Date:  1996-11       Impact factor: 2.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.